Amendments to the Claims

I. Amendments

Please amend claims 1 and 13 as indicated below.

Please add new claims 25-28.

II. The Claims of the Application

Claim 1. (**Currently amended**) A compound of the formula:

R^1-RANTES (2-68)

where R^1 is CH_3-$(CH_2)_n$-X-; in which

X is -C(O)-NH-CH_2-C(O)-, -NHCH_2 -C(O)-, -ONH-CH_2-C(O)-, -OCH_2-CH_2-C(O)-, -CH=CH-C(O)-, -C(O)-, or a covalent bond; and n is an integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:

PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP AVVFVTRKNR QVCANPEKKW VREYINSLEM S

(SEQ ID No. 2) or ~~**a sequence which**~~ is **a polypeptide having** a variant of said sequence, the variant sequence having at least ~~**40 %**~~ **80%** sequence homology with said sequence**;**

wherein said compound inhibits HIV-1 R5 virus infection of PBMCs in vitro;

or a pharmaceutically acceptable salt thereof.

Claim 2. (**Original**) The compound of claim 1, wherein n is 4 and X is -C(O)-NH-CH_2-C(O)-.

Claim 3. (**Original**) The compound of claim 1, wherein n is 5 and X is -NH-CH_2-C(O)-.

Claim 4. (**Original**) The compound of claim 1, wherein n is 7 and X is -C(O)-.

Claim 5. (**Original**) The compound of claim 1, wherein n is 8 and X is a covalent bond.

Claim 6. (**Previously amended**) The compound of claim 1, wherein n is 4 and X is -ONH-CH_2-C(O)- .

Claim 7. (**Previously amended**) The compound of claim 1, wherein n is 5 and X is -CH=CH-C(O)-.

Claim 8. (**Original**) The compound of claim 1, wherein n is 4 and X is -OCH_2-CH_2-C(O)-.

Claim 9-12. (**Cancelled**)

Claim 13. (**Currently amended**) A pharmaceutical composition ~~**for administration to a mammal having a disease state in that is alleviated by treatment with a RANTES inhibitor**~~, which **composition** comprises a therapeutically effective amount of a compound of the formula:

R^1-RANTES (2-68)

where R^1 is CH_3-$(CH_2)_n$-X-; in which

X is -C(O)-NH-CH_2-C(O)-, -$NHCH_2$ -C(O)-, -ONH-CH_2-C(O)-, -OCH_2-CH_2-C(O)-, -CH=CH-C(O)-, -C(O)-, or a covalent bond; and n is an integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:

PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP AVVFVTRKNR QVCANPEKKW VREYINSLEM S

(SEQ ID No. 2) or ~~**a sequence which**~~ is **a polypeptide having** a variant of said sequence, the variant sequence having at least ~~**40%**~~ **80%** sequence homology with said sequence;

wherein said compound inhibits HIV-1 R5 virus infection of PBMCs in vitro;

or a pharmaceutically acceptable salt thereof;

in admixture with one or more pharmaceutically acceptable excipients.

Claim 14-17. (**Cancelled**)

Claim 18. (**Previously added**) The pharmaceutical composition of claim 13, wherein N is 4 and X is -C(O)-NH-CH_2-C(O)-.

Claim 19. (**Previously added**) The pharmaceutical composition of claim 13, wherein N is 5 and X is -NHCH_2 -C(O)- .

Claim 20. (**Previously added**) The pharmaceutical composition of claim 13, wherein N is 7 and X is -C(O)-.

Claim 21 (**Previously added**) The pharmaceutical composition of claim 13, wherein N is 8 and X is a covalent bond.

Claim 22. (**Previously added**) The pharmaceutical composition of claim 13, wherein N is 4 and X is -ONH-CH_2-C(O)- .

Claim 23. (**Previously added**) The pharmaceutical composition of claim 13, wherein N is 5 and X is -CH=CH-C(O)- .

Claim 24. (**Previously added**) The pharmaceutical composition of claim 13, wherein N is 4 and X is -OCH_2-CH_2-C(O)- .

Claims 25-28. (**Cancelled**)

Claim 29. (**New**) A compound of the formula:

R^1-RANTES (2-68)

where R^1 is CH_3-$(CH_2)_n$-X-; in which

X is -C(O)-NH-CH_2-C(O)-, -NHCH_2 -C(O)-, -ONH-CH_2-C(O)-, -OCH_2-CH_2-C(O)-, -CH=CH-C(O)-, -C(O)-, or a covalent bond; and n is an integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:

PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP AVVFVTRKNR QVCANPEKKW VREYINSLEM S

(SEQ ID No. 2) or is a polypeptide having a variant of said sequence, the variant sequence having at least 80% sequence homology with said sequence;

wherein said compound binds to the RANTES CCR5 receptor;

or a pharmaceutically acceptable salt thereof.

Claim 30. (**New**) A pharmaceutical composition, which composition comprises a therapeutically effective amount of a compound of the formula:

R^1-RANTES (2-68)

where R^1 is CH_3-$(CH_2)_n$-X-; in which

X is -C(O)-NH-CH_2-C(O)-, -NHCH_2 -C(O)-, -ONH-CH_2-C(O)-, -OCH_2-CH_2-C(O)-, -CH=CH-C(O)-, -C(O)-, or a covalent bond; and n is an integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:

PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP AVVFVTRKNR QVCANPEKKW VREYINSLEM S

(SEQ ID No. 2) or is a polypeptide having a variant of said sequence, the variant sequence having at least 80% sequence homology with said sequence;

wherein said compound binds to the RANTES CCR5 receptor;

or a pharmaceutically acceptable salt thereof;

in admixture with one or more pharmaceutically acceptable excipients.

Claim 31. (**New**) A compound of the formula:

R^1-RANTES (2-68)

where R^1 is CH_3-$(CH_2)_n$-X-; in which

X is -C(O)-NH-CH_2-C(O)-, -NHCH_2 -C(O)-, -ONH-CH_2-C(O)-, -OCH_2-CH_2-C(O)-, -CH=CH-C(O)-, -C(O)-, or a covalent bond; and n is an integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:

PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP AVVFVTRKNR QVCANPEKKW VREYINSLEM S

(SEQ ID No. 2) or variant of said sequence having from 1 to 20 single amino acid deletions, insertions or substitutions relative to said sequence;

wherein said compound inhibits HIV-1 R5 virus infection of PBMCs in vitro;

or a pharmaceutically acceptable salt thereof.

Claim 32. (**New**) A pharmaceutical composition, which composition comprises a therapeutically effective amount of a compound of the formula:

R^1-RANTES (2-68)

where R^1 is CH_3-$(CH_2)_n$-X-; in which

X is -C(O)-NH-CH_2-C(O)-, -NHCH_2 -C(O)-, -ONH-CH_2-C(O)-, -OCH_2-CH_2-C(O)-, -CH=CH-C(O)-, -C(O)-, or a covalent bond; and n is an integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:

PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP AVVFVTRKNR QVCANPEKKW VREYINSLEM S

(SEQ ID No. 2) or variant of said sequence having from 1 to 20 single amino acid deletions, insertions or substitutions relative to said sequence;

wherein said compound inhibits HIV-1 R5 virus infection of PBMCs in vitro;

or a pharmaceutically acceptable salt thereof;

in admixture with one or more pharmaceutically acceptable excipients.

Claim 33. (**New**) A compound of the formula:

R^1-RANTES (2-68)

where R^1 is CH_3-$(CH_2)_n$-X-; in which

X is -C(O)-NH-CH_2-C(O)-, -NHCH_2 -C(O)-, -ONH-CH_2-C(O)-, -OCH_2-CH_2-C(O)-, -CH=CH-C(O)-, -C(O)-, or a covalent bond; and n is an integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:

PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP AVVFVTRKNR QVCANPEKKW VREYINSLEM S

(SEQ ID No. 2) or variant of said sequence having from 1 to 20 single amino acid deletions, insertions or substitutions relative to said sequence;

wherein said compound binds to the RANTES CCR5 receptor;

or a pharmaceutically acceptable salt thereof.

Claim 34. (**New**) A pharmaceutical composition, which composition comprises a therapeutically effective amount of a compound of the formula:

R^1-RANTES (2-68)

where R^1 is CH_3-$(CH_2)_n$-X-; in which

X is -C(O)-NH-CH_2-C(O)-, -NHCH_2 -C(O)-, -ONH-CH_2-C(O)-, -OCH_2-CH_2-C(O)-, -CH=CH-C(O)-, -C(O)-, or a covalent bond; and n is an integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:

PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP AVVFVTRKNR QVCANPEKKW VREYINSLEM S

(SEQ ID No. 2) or variant of said sequence having from 1 to 20 single amino acid deletions, insertions or substitutions relative to said sequence;

wherein said compound binds to the RANTES CCR5 receptor;

or a pharmaceutically acceptable salt thereof;

in admixture with one or more pharmaceutically acceptable excipients.